Should we be looking at Germany to reduce drug prices

As American lawmakers attempt to stem spiraling drug costs, they might find inspiration in Germany, where the government’s regulatory model has been curbing price growth without thwarting innovation or access. Since 2011, the German government has been requiring drugmakers to prove that a new medication’s benefits merit a higher price if cheaper, similar drugs are available. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.